Ace the CPHON Challenge 2025 – Elevate Your Pediatric Oncology Nursing Game!

The statement that all patients with Fanconi Anemia will eventually develop myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) is false. Fanconi Anemia is a genetic disorder that increases the risk of developing certain malignancies, particularly MDS and AML; however, not every individual with the condition will necessarily progress to these types of cancers.

Fanconi Anemia is characterized by a defect in the DNA repair mechanism, which can lead to hematological abnormalities and predisposition to various cancers. While the lifetime risk of developing MDS or AML is indeed higher in individuals with Fanconi Anemia compared to the general population, many patients may not experience these complications during their lifetime. The variability in outcomes can depend on a range of factors, including the genetic background, environmental exposures, and the severity of the hematologic issues.

Therefore, it is important to note that while there is a significant risk associated with Fanconi Anemia, saying that all patients will develop MDS or AML is inaccurate. This nuanced understanding of the disease highlights the importance of regular monitoring and individualized patient care.